Second Prolibra(R) Study Shows Improved Body Composition By Targeting Fat Loss
Posted on: Wednesday, 6 June 2007, 12:00 CDT
MONROE, Wis., June 6 /PRNewswire/ -- A new report by Glanbia Nutritionals confirms that Prolibra has been clinically proven to have a significant impact on fat loss and muscle mass retention. In the 12-week double-blind, placebo- controlled study, researchers found that adults consuming Prolibra lost 82% more fat than the placebo group, and retained twice as much lean muscle mass.
"We are happy to announce that the results of this second clinical study confirm and significantly strengthen the results of our first human clinical trial, proving that Prolibra is a safe, natural solution to healthy, long-term weight management," said Dr. Eric Bastian, Vice President of Research and Development at Glanbia Nutritionals. "Prolibra is a patent-pending ingredient with GRAS status, which we've successfully formulated into a variety of food, beverage and supplement systems."
Retention of lean muscle mass during dieting contributes to a healthy Basal Metabolic Rate (BMR). This can eliminate the frustrating effects of yo- yo dieting, a common occurrence with traditional diets which fail to address lean muscle mass maintenance. The synergistic effect of Prolibra's unique components, including proprietary whey peptides, contributed to significant fat loss while preserving lean muscle mass.
The 12-week study was designed to measure the effect of Prolibra on body composition. A group of adults (BMI 30 to 42 kg/m2) was randomly divided into a treatment group and a placebo group. The groups were assigned to consume Prolibra or a placebo, twice a day. Both groups were instructed to reduce their caloric intake by 500 calories per day and received dietary counseling. Fifty-nine individuals completed the study.
The results of the study provide the basis for substantiated claims which can be used to support finished products containing Prolibra. According to Sharon Rokosh, Business Development Manager at Glanbia Nutritionals, "We've had the study and resulting claims substantiated by legal review, so our customers can be confident not only in the benefits of Prolibra, but also in how to state them."
For more information on Prolibra research, please send an e-mail to prolibra@glanbianutritionals.com or contact Sharon Rokosh at (608) 329-2800.
Glanbia Nutritionals is a division of Glanbia plc, a leading international food company headquartered in Kilkenny, Ireland. Glanbia plc is one of Europe's leading dairy companies, and one of the world's largest cheese manufacturers.
Glanbia Nutritionals
CONTACT: Kelly Czerwonka, Marketing Manager of Glanbia Nutritionals,Inc., +1-608-329-2800
Source: PRNewswire
Related Articles
- Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
- Research and Markets: Company Study of Fuhuan Group Co., Ltd., 2007 is Available Now
- ICL Group Reports Financial Results for Q3 and First Nine Months of 2006
- ICL Group Reports Q2 Results With Record Sales, $92.3m Net Profit Despite Steep - but Temporary - Potash Decline
- PhytoMedical Announces Key Developmental Partner For New Cachexia Compound, Which Has Active Elements That Increase Lean Muscle Mass and Reduce Body Fat
- Restaurants Can Now Offer Healthier Fried Foods Without Compromising Taste or Performance; Studies Confirm Healthier Oils -- With Zero Trans Fats, Lower Saturated Fats -- Also Provide Great Taste, Long Fry Life
- Group Seeks Ban on Fat-Blocking Pill
- Vodafone Group Plc IFRS Results For The Year Ended 31 March 2005
- Glycemic and Lipid Control in Hospitalized Type 2 Diabetic Patients: Evaluation of 2 Enteral Nutrition Formulas (Low Carbohydrate-High Monounsaturated Fat Vs High Carbohydrate)
 |
 |
User Comments (0)
RSS Feeds